Beijing Airdoc Technology Co., Ltd.
北 京 鷹 瞳 科 技 發 展 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2251)

PROFIT WARNING

This announcement is made by Beijing Airdoc Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors ("**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment by the Board of the Group's draft unaudited consolidated management accounts for the year ended December 31, 2024 and other information currently available to the Board, the Group expects to record an unaudited loss ranging from RMB250 million to RMB270 million for the year ended December 31, 2024 (December 31, 2023: a loss of RMB145.7 million), and an unaudited loss attributable to the owners of the parent ranging from RMB240 million to RMB250 million for the year ended December 31, 2024 (December 31, 2023: a loss attributable to the owners of the parent of RMB132.5 million).

The Board is of the preliminary view that, the widening of losses for the year ended December 31, 2024 is mainly due to the change in the regulatory framework affecting the Group's laser-based Myopia Treatment AI (the "**Affected Products**"). As disclosed in the interim report of the Group for the six months ended June 30, 2024, the National Medical Products Administration promulgated a new regulation in June 2023 that prohibited the production and sale of relevant laser-based myopia treatment devices from July 1, 2024. This regulatory change has resulted in (i) a reduction in revenue from the Affected Products; (ii) the recognition of an impairment on the goodwill associated with the Company's acquired myopia prevention and treatment business through the acquisition of an equity interest in Beijing Zhitong Technology Co., Ltd. (北京智瞳科技有限公司) ("**Beijing Zhitong**"); (iii) a loss allowance recorded for a sales contract of the Affected

Products, as this regulatory change has also adversely affected the business activities of the Company's customers and their related transactions; and (iv) an increase in research and development expenses allocated to product upgrading, reflecting the Company's ongoing efforts to adapt its product portfolio to evolving regulatory requirements.

The Group's Photobiomodulation ("**PBM**") LED-based Myopia Treatment AI (another tech route started by Beijing Zhitong) has received regulatory approval. Driven by the rising prevalence of myopia among young people in recent years and the proven efficacy of the Company's products, the Board is confident that the Company's PBM LED-based myopia prevention and treatment product will deliver significant benefits to users while driving revenue growth.

As of the date of this announcement, the Company is still in the process of finalizing its consolidated financial results of the Group for the year ended December 31, 2024. The information contained in this announcement is prepared only based on the information currently available to the Board and a preliminary assessment of the Group's unaudited consolidated management accounts for the year ended December 31, 2024 which have not been confirmed, reviewed or audited by the independent auditor of the Company, or reviewed by the audit committee of the Board. It shall not be considered as a measure or indicator of the future financial performance of the Group. The audited results of the Group for the year ended December 31, 2024 may differ from what is disclosed in this announcement.

Shareholders and potential investors are advised to refer to the results announcement of the Company in respect of the Group for the year ended December 31, 2024, which is expected to be released in March 2025 in accordance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, March 11, 2025

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Dr. HE Chao and Mr. Qin Yong as executive Directors; and Dr. WU Yangfeng, Dr. HUANG Yanlin and Mr. Ng Ho Yin Owen as independent non-executive Directors.